[go: up one dir, main page]

PE20181207A1 - Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana - Google Patents

Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana

Info

Publication number
PE20181207A1
PE20181207A1 PE2018000720A PE2018000720A PE20181207A1 PE 20181207 A1 PE20181207 A1 PE 20181207A1 PE 2018000720 A PE2018000720 A PE 2018000720A PE 2018000720 A PE2018000720 A PE 2018000720A PE 20181207 A1 PE20181207 A1 PE 20181207A1
Authority
PE
Peru
Prior art keywords
treatment
immunodeficiency virus
human immunodeficiency
therapeutic compositions
pharmaceutically acceptable
Prior art date
Application number
PE2018000720A
Other languages
English (en)
Inventor
Lei Hong
Benjamin Micah Collman
Joanna M Koziara
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57346085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20181207A1 publication Critical patent/PE20181207A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona una forma de dosificacion oral solida, que comprende un compuesto de Formula I o una sal farmaceuticamente aceptable del mismo, tenofovir alafenamida o una sal farmaceuticamente aceptable de la misma, y emtricitabina o una sal farmaceuticamente aceptable de la misma.
PE2018000720A 2015-11-09 2016-11-08 Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana PE20181207A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562253042P 2015-11-09 2015-11-09
US201662399999P 2016-09-26 2016-09-26

Publications (1)

Publication Number Publication Date
PE20181207A1 true PE20181207A1 (es) 2018-07-23

Family

ID=57346085

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000720A PE20181207A1 (es) 2015-11-09 2016-11-08 Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana

Country Status (27)

Country Link
US (4) US10548846B2 (es)
EP (2) EP3346995B1 (es)
JP (1) JP6621933B2 (es)
KR (4) KR102606625B1 (es)
CN (2) CN113546052A (es)
AU (2) AU2016354007C9 (es)
BR (1) BR102016026127A2 (es)
CA (1) CA2948021C (es)
CL (1) CL2018001199A1 (es)
CO (1) CO2018004776A2 (es)
CR (1) CR20180253A (es)
EA (1) EA201890654A1 (es)
EC (1) ECSP18033723A (es)
ES (1) ES2757560T3 (es)
IL (1) IL258459A (es)
MX (1) MX2018005729A (es)
NZ (1) NZ741957A (es)
PE (1) PE20181207A1 (es)
PH (1) PH12018501001A1 (es)
PL (1) PL3346995T3 (es)
PT (1) PT3346995T (es)
SG (1) SG11201802983TA (es)
SI (1) SI3346995T1 (es)
SV (1) SV2018005682A (es)
TW (2) TW202220660A (es)
UY (1) UY36981A (es)
WO (1) WO2017083304A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4841B1 (ro) 2012-12-21 2023-01-31 Gilead Sciences, Inc. Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2019030625A1 (en) * 2017-08-09 2019-02-14 Viiv Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
WO2019030626A1 (en) * 2017-08-09 2019-02-14 Viiv Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
KR20240011880A (ko) 2017-12-07 2024-01-26 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
KR102879944B1 (ko) * 2018-09-19 2025-11-03 길리애드 사이언시즈, 인코포레이티드 Hiv 예방용 인테그라제 억제제
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法
CN119174736A (zh) * 2024-09-09 2024-12-24 安徽贝克生物制药有限公司 一种三联复方片及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331208A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸
HRP20160074B1 (hr) 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JP2006506352A (ja) 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物
US20060234982A1 (en) 2003-01-14 2006-10-19 Dahl Terrence C Compositions and methods for combination antiviral therapy
WO2006030807A1 (ja) 2004-09-15 2006-03-23 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
PL3284520T3 (pl) 2005-04-28 2020-01-31 Viiv Healthcare Company Policykliczna pochodna karbamoilopirydonu mająca aktywność hamowania integrazy HIV
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
HRP20080313A2 (en) 2005-12-30 2008-11-30 Gilead Sciences Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2008043829A2 (en) 2006-10-14 2008-04-17 Boehringer Ingelheim International Gmbh Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
HRP20151009T1 (hr) 2009-02-06 2015-10-23 Gilead Sciences, Inc. Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir
SG10201912527XA (en) * 2010-11-19 2020-02-27 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
BR112014000290B1 (pt) 2011-07-07 2022-05-10 Gilead Sciences, Inc. Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir
CN110343135A (zh) 2011-08-16 2019-10-18 吉利德科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
NZ629896A (en) * 2012-02-03 2016-03-31 Gilead Sciences Inc Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MD4841B1 (ro) 2012-12-21 2023-01-31 Gilead Sciences, Inc. Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
NO2865735T3 (es) * 2013-07-12 2018-07-21
EA201690146A1 (ru) * 2013-08-14 2016-07-29 Ратиофарм Гмбх Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
CN119606990A (zh) 2015-06-30 2025-03-14 吉利德科学公司 包含替诺福韦和恩曲他滨的药物制剂
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
KR102100436B1 (ko) 2018-10-30 2020-04-13 울산과학기술원 강자성 원소 치환형 상온 다강성 물질 및 그 제조 방법

Also Published As

Publication number Publication date
SV2018005682A (es) 2018-08-15
US20220378798A1 (en) 2022-12-01
CO2018004776A2 (es) 2018-06-20
PT3346995T (pt) 2019-11-22
AU2020200995B9 (en) 2022-04-28
PH12018501001A1 (en) 2018-12-17
US20210052502A1 (en) 2021-02-25
WO2017083304A8 (en) 2018-04-19
TW202220660A (zh) 2022-06-01
WO2017083304A1 (en) 2017-05-18
KR20230015512A (ko) 2023-01-31
AU2016354007C9 (en) 2020-10-01
AU2020200995B2 (en) 2022-04-07
CL2018001199A1 (es) 2018-09-28
JP6621933B2 (ja) 2019-12-18
CR20180253A (es) 2018-07-16
CN108348473A (zh) 2018-07-31
KR102153996B1 (ko) 2020-09-09
US11744802B2 (en) 2023-09-05
NZ741957A (en) 2019-04-26
US20170189337A1 (en) 2017-07-06
CN108348473B (zh) 2021-06-18
US20260027061A1 (en) 2026-01-29
CA2948021A1 (en) 2017-05-09
AU2016354007B2 (en) 2019-11-14
ES2757560T3 (es) 2020-04-29
SI3346995T1 (sl) 2019-11-29
KR20200106222A (ko) 2020-09-11
ECSP18033723A (es) 2018-05-31
TWI737647B (zh) 2021-09-01
CN113546052A (zh) 2021-10-26
EP3346995B1 (en) 2019-08-28
JP2018532811A (ja) 2018-11-08
EA201890654A1 (ru) 2018-10-31
KR20180067702A (ko) 2018-06-20
HK1256903A1 (en) 2019-10-04
UY36981A (es) 2017-06-30
BR102016026127A2 (pt) 2017-05-16
AU2016354007A1 (en) 2018-05-10
IL258459A (en) 2018-05-31
SG11201802983TA (en) 2018-05-30
US10548846B2 (en) 2020-02-04
AU2016354007C1 (en) 2020-09-10
EP3632415A1 (en) 2020-04-08
AU2016354007A8 (en) 2018-06-14
KR20240095320A (ko) 2024-06-25
AU2020200995A1 (en) 2020-02-27
CA2948021C (en) 2024-06-18
EP3346995A1 (en) 2018-07-18
KR102606625B1 (ko) 2023-11-27
MX2018005729A (es) 2018-08-09
TW201726139A (zh) 2017-08-01
PL3346995T3 (pl) 2020-03-31
HK1256093A1 (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
EA201792591A1 (ru) Фармацевтические препараты
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CR20160527A (es) Derivados de carboxamida
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
UY36123A (es) Derivados de carboxamida
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
AR106645A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
EA201992754A1 (ru) Фармацевтические композиции
UA112089C2 (uk) Тверда лікарська форма комбінованого препарату седативної та снодійної дії, що містить доксиламін